Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CIRCANOL vs ISMO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CIRCANOL (flupentixol) is a thioxanthene derivative that acts as a dopamine D1/D2 receptor antagonist, with higher affinity for D2 receptors, and also exhibits antagonism at serotonin 5-HT2 receptors. It modulates neurotransmission in the mesolimbic and mesocortical pathways, reducing positive symptoms of schizophrenia and exerting antidepressant effects at low doses via presynaptic dopamine receptor blockade.
Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.
Schizophrenia (maintenance therapy),Other psychotic disorders,Depression (low-dose augmentation in resistant cases)
Prevention of angina pectoris due to coronary artery disease,Off-label: Treatment of acute angina (immediate-release forms)
4 mg orally once daily.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.
Terminal elimination half-life is 14-18 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 5-6 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged (up to 8-10 hours), warranting dose adjustment.
Primarily hepatic via CYP2D6 and CYP3A4, forming metabolites including N-dealkylated and sulfoxide derivatives; undergoes extensive first-pass metabolism.
Primarily metabolized in the liver by denitration; minor metabolism via glucuronidation. Metabolites are inactive.
Primarily renal (70-90% unchanged) with minor biliary/fecal (5-15%)
Primarily renal; 80-90% of the dose is excreted as inactive metabolites (isosorbide mononitrate and isosorbide dinitrate) in urine. Less than 1% is excreted unchanged. Fecal excretion is minimal.
40-50% bound to albumin and α1-acid glycoprotein
Approximately 30% bound to plasma proteins, primarily albumin.
1.2-1.8 L/kg; indicates extensive extravascular distribution, possibly due to tissue binding.
Vd is 0.6-0.9 L/kg, indicating distribution into total body water. Higher Vd may be observed in patients with heart failure.
Oral: 60-75% due to first-pass metabolism
Oral: 90-100% (sustained-release formulations). Sublingual: high but variable; generally effective due to extensive absorption.
No dose adjustment required for GFR ≥30 m L/min; not recommended for use if GFR <30 m L/min.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose to 10 mg twice daily due to potential accumulation of active metabolite.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 2 mg once daily; Child-Pugh C: not recommended.
No dose adjustment in Child-Pugh A or B. For Child-Pugh C, reduce dose to 10 mg twice daily and monitor for hypotension.
Not approved for pediatric use; safety and efficacy not established.
Safety and efficacy not established; no standard dosing recommendations.
Start at 2 mg orally once daily; increase to 4 mg as tolerated based on response and renal function.
Start at 10 mg twice daily with gradual titration based on tolerance and renal function. Monitor for hypotension and dizziness.
None
Do not use with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Extrapyramidal symptoms (acute dystonia, akathisia, parkinsonism); tardive dyskinesia with long-term use; neuroleptic malignant syndrome; QT interval prolongation; increased mortality in elderly patients with dementia-related psychosis; seizures; hepatic impairment; hematologic effects (leukopenia, neutropenia); anticholinergic effects; orthostatic hypotension; hyperprolactinemia.
Hypotension and reflex tachycardia may occur,Caution in patients with volume depletion or hypotension,May cause headaches; tolerance may develop with prolonged use,Abrupt withdrawal may increase angina frequency
Comatose states; CNS depression; severe liver disease; blood dyscrasias; pheochromocytoma; known hypersensitivity to flupentixol or other thioxanthenes; concurrent use with dopamine agonists (except in Parkinson's disease psychosis).
Concurrent use of PDE-5 inhibitors,Severe anemia,Closed-angle glaucoma,Hypersensitivity to isosorbide mononitrate or nitrates,Acute myocardial infarction with low filling pressures
Avoid grapefruit and grapefruit juice as they may increase drug levels and risk of side effects. No other significant food interactions. Maintain adequate hydration to prevent hypotension.
Alcohol may enhance hypotension risk. Avoid high-fat meals if extended-release formulation, as they may affect absorption. No other significant food interactions.
First trimester: Evidence of human fetal harm based on retrospective studies showing increased risk of congenital anomalies (cardiac defects, neural tube defects) with first-trimester exposure. Second and third trimesters: Risk of fetal hypotension, neonatal respiratory depression, and withdrawal syndrome with chronic use; avoid near term due to risk of premature ductus arteriosus closure.
ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate human studies exist. Use only if potential benefit justifies risk. First trimester: Theoretical risk of hemodynamic effects; avoid unless necessary. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; monitor fetal heart rate. Peripartum: May exacerbate uterine relaxation and postpartum hemorrhage if used near delivery.
Small amounts excreted into breast milk (M/P ratio approximately 0.3-0.5). Considered compatible with breastfeeding due to limited oral bioavailability in infants; however, monitor infant for sedation or poor feeding.
Excretion into human milk is unknown. Due to risk of infant methemoglobinemia and hypotension, caution is advised. M/P ratio: Not available. American Academy of Pediatrics considers nitrate derivatives compatible with breastfeeding, but monitor infant for cyanosis and lethargy.
Increased volume of distribution and renal clearance in pregnancy may necessitate higher doses to maintain therapeutic effect; however, due to fetal risks, use lowest effective dose for shortest duration. No standard dose adjustment; individualize based on clinical response and tolerability.
No specific dose adjustments for ISMO in pregnancy are established due to lack of pharmacokinetic studies. However, pregnancy-induced hemodynamic changes (increased plasma volume, cardiac output) may reduce efficacy; consider dose titration based on clinical response. Avoid doses >60 mg/day to minimize hypotensive risk. Use immediate-release formulations for flexible dosing if needed.
Circanol (ergoloid mesylates) is a vasodilator used primarily for age-related cognitive decline. Monitor for orthostatic hypotension, especially in elderly patients. Onset of benefit may take several weeks; discontinue if no response after 3-6 months. Avoid use in patients with a history of psychosis or severe hypotension. Can be used as adjunctive therapy for dementia but not a first-line agent.
ISMO (isosorbide mononitrate) is a nitrate used for angina prophylaxis, not for acute attacks. Tolerance develops with sustained use; maintain a 10-12 hour nitrate-free interval to prevent tolerance. Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of profound hypotension. Contraindicated in severe anemia, increased intracranial pressure, or hypertrophic obstructive cardiomyopathy. Discontinue if blurred vision or dry mouth occurs.
Take Circanol exactly as prescribed; do not stop abruptly.,Rise slowly from sitting or lying to prevent dizziness or falls.,Report any fainting, rapid heart rate, or severe headache immediately.,Avoid alcohol as it may worsen side effects like dizziness and low blood pressure.,Improvement in symptoms may take 4-12 weeks; continue medication as directed even if no immediate benefit.
Take as prescribed to prevent angina; do not use for acute attacks.,May cause headache, dizziness, or hypotension; rise slowly from sitting.,Avoid taking erectile dysfunction drugs (e.g., sildenafil, tadalafil) as severe blood pressure drop can occur.,Do not stop abruptly to avoid rebound angina.,Store in original container away from light and moisture.
No interactions on record
"Bosentan, a dual endothelin receptor antagonist and an inducer of CYP3A4 and CYP2C9, reduces systemic exposure to vismodegib, a Hedgehog pathway inhibitor primarily metabolized by CYP3A4. This interaction leads to decreased serum concentrations of vismodegib, potentially diminishing its antitumor efficacy in patients with advanced basal cell carcinoma. Concomitant use may require vismodegib dose adjustment or alternative therapies to avoid therapeutic failure."
"Vismodegib inhibits CYP3A4, which is the primary enzyme responsible for metabolizing nilotinib. Concomitant administration may lead to increased nilotinib plasma concentrations, elevating the risk of QT interval prolongation, torsades de pointes, hepatotoxicity, and myelosuppression. Clinical vigilance is warranted due to the narrow therapeutic index of nilotinib."
"Vismodegib, a hedgehog pathway inhibitor, is a moderate inhibitor of CYP2C9, the primary enzyme responsible for metabolizing tolbutamide. Concomitant use can significantly decrease tolbutamide clearance, leading to elevated plasma concentrations and prolonged hypoglycemic effects. This increases the risk of severe hypoglycemia, especially in diabetic patients, and may require dose adjustment of tolbutamide."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CIRCANOL vs ISMO, answered by our medical review team.
CIRCANOL is a Vasodilator (Peripheral) that works by CIRCANOL (flupentixol) is a thioxanthene derivative that acts as a dopamine D1/D2 receptor antagonist, with higher affinity for D2 receptors, and also exhibits antagonism at serotonin 5-HT2 receptors. It modulates neurotransmission in the mesolimbic and mesocortical pathways, reducing positive symptoms of schizophrenia and exerting antidepressant effects at low doses via presynaptic dopamine receptor blockade.. ISMO is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CIRCANOL and ISMO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CIRCANOL is: 4 mg orally once daily.. The standard adult dose of ISMO is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CIRCANOL and ISMO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CIRCANOL is classified as Category C. First trimester: Evidence of human fetal harm based on retrospective studies showing increased risk of congenital anomalies (cardiac defects, neural tube defects) with first-trimes. ISMO is classified as Category C. ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.